Met Exon 14 Skipping Metastatic Non Small Cell Lung Cancer Therapeutics
1. Tepmetko patent expiration
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(4 years from now) | |
| US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(3 years from now) | |
| US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(2 years from now) | |
| US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(2 years from now) | |
| US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(2 years from now) | |
| US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(2 years from now) | |
| US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2026 |
| Orphan Drug Exclusivity(ODE-325) | Feb 03, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 February, 2025
Market Authorisation Date: 03 February, 2021
Dosage: TABLET
More Information on Dosage
TEPMETKO family patents
